Skip to content
lifestyle.brownplanet.com
Animals
Auto
Beauty & Style
Business News
Entertainment
Food
Health
Home & Family
Podcasts
Tech
Travel
Author:
Oblenio Bio, Inc.
Oblenio Bio Closes $62 Million Series B to Advance Tri-specific T-Cell Engager LBL-051 for Autoimmune Diseases into Clinical Development
June 25, 2026